In this article
Surging demand for weight loss and diabetes drugs leaves the pharmaceutical sector at risk from a “bubble effect” as profitability soars, new research suggests.
Demand for the likes of Wegovy and Zepbound has driven research and development returns to their highest level in years, but a report published by Deloitte on Monday suggests this is masking pressure facing the rest of the sector.
Pharmaceutical R&D returns for the world’s top 20 pharma companies have improved for a third consecutive year to 7%, thanks almost entirely to a handful of high-forecast assets such as glucagon-like peptide receptor agonists, or GLP-1s.
The report found that, for the first time in 16 years, oncology has been surpassed as the largest contributor to late-stage pipeline value by obesity treatments.
